abbrevi
sar
sever
acut
respiratori
syndrom
cov
coronaviru
plpro
papainlik
proteinas
proteas
dub
deubiquitin
enzym
amc
fret
fluoresc
reson
energi
transfer
v
l
b
l
e
w
w
w
c
e
n
c
e
r
e
c
c
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
b
c
h
e
p
h
r
see
front
matter
sever
acut
respiratori
syndrom
sar
lifethreaten
atyp
pneumonia
caus
sar
coronaviru
sarscov
outbreak
viru
infect
peopl
fatal
rate
human
high
world
health
organ
easi
transmiss
human
make
reemerg
sarscov
distinct
possibl
entail
urgent
need
prepar
antivir
drug
sarscov
date
effect
antisar
drug
avail
proven
efficaci
vivo
although
vaccin
monoclon
antibodi
sarscov
develop
compound
competit
select
revers
inhibitor
plpro
k
valu
mm
structurefunct
relationship
studi
identifi
thiocarbonyl
moieti
activ
pharmacophor
essenti
inhibit
report
inhibit
select
compound
exert
signific
inhibitori
effect
cystein
proteas
includ
sarscov
sever
cathepsin
thu
result
present
first
potenti
chemic
lead
sarscov
plpro
might
use
lead
compound
optim
enhanc
potenc
sarscov
still
use
extens
clinic
especi
children
acut
lymphoblast
myeloblast
leukemia
light
possibl
inhibit
subset
cystein
proteas
studi
emphas
import
studi
depth
drug
action
vivo
elsevi
inc
right
reserv
sarscov
plusstrand
rna
viru
encod
four
structur
protein
nonstructur
protein
accessori
protein
nonstructur
protein
cleavag
product
larg
polypeptid
gener
viral
encod
proteas
proteas
papainlik
proteas
plpro
ec
sarscov
also
encod
helicas
multipl
enzymat
activ
vitro
includ
rnadna
helicas
nucleas
rna
activ
rnadepend
rna
polymeras
extens
indepth
investig
sarscov
led
identif
cellular
receptor
carboxypeptidas
angiotensinconvert
enzym
determin
structur
mani
viral
structur
nonstructur
protein
understand
function
mani
viral
protein
vivo
intens
hunt
effect
antisar
drug
undertaken
includ
screen
exist
antivir
market
drug
possibl
antisar
effect
inhibitor
design
discov
target
differ
compon
viru
includ
interact
viral
protein
host
receptor
mediat
fusion
viral
entri
cathepsin
l
decreas
membran
fusion
rnadepend
rna
polymeras
helicas
far
compound
predominantli
test
vitro
efficaci
human
clinic
trial
ever
initi
recent
anim
model
mimic
mortal
human
diseas
syndrom
induc
mouseadapt
sarscov
set
provid
opportun
test
effect
inhibitor
vivo
efficaci
proteas
remain
one
promin
effect
drug
target
antivir
therapi
includ
direct
human
immunodefici
viru
hepat
c
viru
viral
infect
proteolyt
process
essenti
gener
function
replic
complex
plpro
potenti
effect
target
antisar
drug
effort
report
focus
develop
inhibitor
howev
except
previou
observ
zinc
ion
inhibit
plpro
sarscov
inhibitor
proteas
yet
report
plpro
sarscov
papainlik
cystein
proteas
deubiquitin
activ
locat
polypeptid
selfcleav
three
site
polypeptid
catalyt
triad
broad
rang
ph
optima
characterist
papainlik
cystein
proteas
moreov
plpro
deubiquitin
activ
vitro
capabl
hydrolyz
diubiquitin
polyubiquitin
synthet
ubiquitin
peptid
substrat
recent
crystal
structur
solv
show
great
similar
two
mammalian
deubiquitin
enzym
dub
herpesvirusassoci
uiquitinspecif
proteas
hausp
despit
low
sequenc
ident
around
three
protein
share
similar
tripartit
architectur
compris
finger
palm
thumb
domain
also
ubiquitinlik
domain
amino
terminu
plpro
might
respons
associ
proteasom
observ
yeast
dub
call
plpro
also
deisgyl
activ
ubiquitinlik
protein
involv
posttransl
modif
protein
biolog
function
deubiquitin
deisgyl
activ
plpro
vivo
substrat
unknown
present
previous
develop
fluoresc
reson
energi
transfer
fret
assay
screen
inhibitor
plpro
highthroughput
format
report
discoveri
inhibit
sarscov
plpro
purin
analogu
effect
treatment
patient
acut
lymphoblast
myeloblast
leukemia
structureact
relationship
inhibit
mechan
investig
knowledg
first
chemic
compound
report
revers
inhibitor
plpro
implic
use
antivir
therapi
discuss
materi
method
ninta
agaros
qiagen
inc
valencia
ca
usa
compound
librari
use
genesi
plu
collect
purchas
microsourc
discoveri
system
inc
gaylordsvil
ct
usa
librari
contain
mani
compound
alreadi
approv
unit
state
food
drug
administr
fda
hypoxanthin
nethylmaleimid
nem
sigmaaldrich
corpor
inc
loui
st
usa
fluka
inc
buch
sg
switzerland
acro
organ
thermo
fisher
scientif
inc
waltham
usa
papainlik
cystein
proteas
cathepsin
b
l
k
prepar
describ
previous
wherea
papain
sigmaaldrich
corpor
inc
purifi
homogen
calpain
test
studi
activ
titrat
sigmaaldrich
corpor
inc
plpro
express
plasmid
construct
amplifi
plpro
cdna
pcr
primer
use
previous
construct
plasmid
templat
cdna
fragment
releas
bamhi
xhoi
digest
ligat
vector
tag
c
terminu
novagen
plpro
express
escherichia
coli
cell
induc
mm
iptg
cultur
overnight
collect
centrifug
g
min
cell
pellet
sonic
buffer
contain
mm
imidazol
mm
sodium
chlorid
mm
trishcl
ph
suspens
clear
centrifug
g
min
supernat
incub
ninta
slurri
qiagen
min
load
column
column
wash
buffer
contain
mm
imidazol
mm
sodium
chlorid
mm
trishcl
ph
plpro
protein
elut
buffer
contain
mm
imidazol
mm
sodium
chlorid
mm
trishcl
ph
protein
store
mm
phosphat
buffer
ph
buffer
exchang
amicon
centrifug
filter
devic
millipor
typic
yield
protein
mg
per
liter
cell
cultur
purif
measur
enzymat
activ
sarscov
perform
describ
previous
inhibitor
screen
carri
describ
previous
deubiquitin
assay
plpro
nm
incub
chemic
compound
min
substrat
ubiquitinamc
mm
ad
mm
phosphat
buffer
ph
enzymat
activ
determin
monitor
enhanc
fluoresc
emiss
upon
substrat
cleavag
excit
emiss
wavelength
nm
respect
perkinelm
ls
luminesc
spectromet
usa
slightli
solubl
assay
buffer
use
dabcylfrlkggapikgvedan
instead
abzfrlkggapikgvedan
substrat
measur
enzymat
activ
plpro
throughout
cours
studi
describ
specif
enhanc
fluoresc
emiss
upon
substrat
cleavag
monitor
excit
emiss
wavelength
nm
respect
perkinelm
ls
luminesc
spectromet
fluoresc
intens
convert
amount
hydrolyz
substrat
use
standard
curv
drawn
fluoresc
measur
welldefin
concentr
dabcylfrlkgg
apikgvedan
peptid
ratio
also
correct
inner
filter
effect
substrat
kinet
analysi
reaction
mixtur
contain
mm
peptid
substrat
mm
phosphat
buffer
ph
total
volum
ml
addit
enzym
reaction
mixtur
increas
fluoresc
nm
excit
nm
continu
monitor
perkinelm
ls
luminesc
spectromet
increas
fluoresc
linear
least
min
thu
slope
line
repres
initi
veloc
v
steadyst
kinet
paramet
enzym
determin
fit
michaelismenten
equat
eq
initi
veloc
data
v
max
maximum
reaction
rate
denot
substrat
concentr
k
michaelismenten
constant
interact
peptid
substrat
enzym
inhibit
studi
mm
peptid
substrat
mm
mix
plpro
mm
fluoresc
intens
monitor
specif
enhanc
fluoresc
emiss
upon
substrat
cleavag
monitor
excit
emiss
wavelength
nm
respect
perkinelm
ls
luminesc
spectromet
fluoresc
intens
convert
amount
hydrolyz
substrat
use
standard
curv
drawn
fluoresc
measur
welldefin
concentr
dabcylfrlkgg
apikgvedan
peptid
ratio
enzymat
activ
assay
inhibit
data
best
fit
competit
inhibit
pattern
accord
eq
inhibitor
concentr
k
slope
inhibit
constant
enzymeinhibitor
complex
inactiv
studi
use
plpro
enzym
mm
mm
phosphat
buffer
ph
incub
differ
concentr
mm
h
aliquot
withdrawn
differ
time
point
ad
assay
mixtur
contain
mm
peptid
substrat
determin
remain
enzym
activ
substrat
hydrolysi
presenc
inhibitor
linear
first
min
good
fit
pseudofirstord
rate
equat
eq
experiment
data
obtain
e
enzym
activ
time
zero
e
enzym
activ
time
slope
semilog
plot
repres
observ
inactiv
rate
constant
k
inact
studi
inactiv
plpro
enzym
mm
mm
phosphat
buffer
ph
incub
differ
concentr
mm
presenc
peptid
substrat
enzymat
activ
trace
min
progress
curv
record
show
exponenti
approach
final
linear
rate
analyz
leastsquar
fit
follow
integr
rate
equat
eq
ref
experiment
data
v
initi
veloc
v
steadyst
veloc
displac
yaxi
replot
k
inact
versu
concentr
linear
therefor
fit
satur
curv
accord
eq
k
inact
dissoci
constant
complex
k
max
maximum
inactiv
rate
constant
comput
model
plpro
complex
crystal
structur
sarscov
plpro
pdb
code
pdb
code
use
templat
dock
perform
ds
model
softwar
accelri
dock
size
space
grid
point
near
activ
site
chosen
structur
creat
separ
specifi
input
ligand
dock
experi
chemic
flexibl
allow
interact
energi
adopt
forc
field
charg
method
grid
extens
site
nonbond
cutoff
distanc
soften
potenti
energi
distancedepend
dielectr
use
dielectr
constant
dock
result
calibr
mont
carlo
trial
maxim
torsion
possibl
pose
compar
express
purifi
plpro
e
coli
describ
section
purifi
proteas
ran
around
kda
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
puriti
data
shown
mass
analysi
also
carri
determin
homogen
enzym
prepar
singl
peak
around
molecular
mass
observ
close
predict
da
data
shown
assay
peptid
substrat
condit
similar
report
previous
plpro
prepar
exhibit
similar
kinet
properti
plpro
isol
insect
cell
specif
activ
mmol
min
mg
use
substrat
dabcylfrlkggapikgvedan
compar
mmol
min
mg
insect
cell
use
substrat
abzfrlkggapikgvedan
suggest
express
system
major
influenc
properti
identifi
potent
inhibitor
sarscov
plpro
screen
librari
contain
compound
use
screen
platform
establish
previous
interestingli
found
apart
zinc
ion
thiocarbonylcontain
compound
compound
effect
inhibitor
sarscov
plpro
ic
valu
mm
respect
tabl
nem
compound
commonli
use
cystein
proteas
inhibitor
act
coval
modifi
activesit
cy
michael
addit
also
found
effect
inhibitor
plpro
ic
valu
mm
howev
investig
plpro
deubiquitin
enzym
structur
highli
homolog
dub
next
test
whether
also
inhibit
deubiquitin
activ
plpro
use
ubiquitinamc
substrat
found
zn
effect
inhibit
deubiquitin
activ
plpro
fig
determin
whether
inhibit
revers
first
incub
enzym
activ
enzym
could
detect
next
enzym
purifi
gel
filtrat
follow
new
activ
measur
enzymat
activ
restor
suggest
enzymeinhibitor
complex
dissoci
column
andor
dilut
assay
buffer
indic
revers
inhibit
identifi
activ
pharmacophor
inhibit
structurefunct
relationship
studi
carri
substructur
search
base
structur
carri
use
softwar
isi
http
wwwisisrlacuk
dataanalysi
mdl
avail
chemic
directori
mdl
acd
sinc
major
differ
adenosin
lie
thiocarbonyl
group
search
differ
substitut
group
site
databas
compound
discov
avail
purchas
commerci
section
replac
thiocarbonyl
either
hydroxyl
compound
methylthio
group
compound
result
compound
devoid
inhibitori
activ
tabl
suggest
thiocarbonyl
group
activ
pharmacophor
inhibit
gain
insight
inhibit
mechan
dock
experi
perform
plpro
exist
monom
solut
crystal
form
three
monom
exist
asymmetr
unit
activ
site
three
unit
data
shown
chose
subunit
one
model
studi
fit
well
activesit
caviti
plpro
sulfur
atom
juxtapos
close
gs
distanc
suggest
possibl
format
hydrogen
bond
fig
consist
activ
chemic
properti
thiocarbonyl
group
best
dock
score
bind
plpro
respect
moreov
bind
energi
plpro
kcalmol
respect
understand
kinet
mechan
interact
enzym
enzymat
activ
measur
seri
substrat
concentr
variou
inhibitor
concentr
inhibit
data
global
fit
possibl
kinet
model
competit
noncompetit
uncompetit
mix
competit
shown
fig
simpl
competit
inhibit
pattern
best
describ
data
follow
two
reason
doubl
reciproc
plot
line
intercept
yaxi
fig
fig
ii
slope
versu
inhibitor
concentr
replot
linear
fig
inset
therefor
consist
dock
result
fig
may
compet
peptid
substrat
activ
site
via
competit
mechan
best
fit
eq
experiment
data
yield
k
valu
mm
respect
tabl
summar
tabl
ph
rang
shown
previous
optim
enzymat
activ
plpro
k
valu
substrat
hydrolysi
absenc
inhibitor
rang
mm
wherea
k
cat
valu
rang
micha
constant
k
substrat
inhibit
constant
k
k
inact
similar
understand
kinet
mechan
inhibit
timedepend
chang
enzym
activ
function
inhibitor
concentr
determin
preincub
plpro
enzym
differ
concentr
inhibitor
prior
measur
enzym
activ
semilog
plot
e
e
versu
time
linear
initi
stage
fig
pseudofirstord
rate
constant
k
inact
differ
inhibitor
concentr
follow
satur
kinet
fig
emiss
curv
curv
downward
indic
slowbind
mechan
fig
fit
data
eq
fig
section
differ
k
inact
valu
variou
concentr
determin
fig
fit
satur
curvatur
eq
determin
k
inact
valu
mm
respect
k
max
inactiv
ms
respect
tabl
slightli
potent
inhibitor
indic
slightli
lower
k
inact
eightfold
higher
k
max
summari
slowbind
inhibitor
sarscov
plpro
although
bind
affin
plpro
similar
peptid
substrat
tabl
base
kinet
model
result
propos
follow
kinet
mechan
fig
might
form
hydrogen
bond
enzym
activ
site
thio
moieti
thiocarbonyl
group
hydrogen
bond
block
essenti
sulfhydryl
group
prevent
acyl
inhibit
enzym
activ
activ
inhibitor
cystein
proteas
next
investig
whether
inhibit
cystein
proteas
initi
sarscov
proteas
also
cystein
proteas
test
possibl
inhibit
comparison
plpro
therefor
made
mm
inhibitor
concentr
h
incub
time
wherea
inhibitor
concentr
almost
complet
abolish
activ
plpro
residu
activ
found
much
less
effect
inhibitor
residu
activ
respect
next
step
also
use
molecular
model
dock
inhibitor
best
dock
score
respect
lower
respect
moreov
bind
energi
kcalmol
respect
lower
plpro
kcalmol
respect
final
sulfur
atom
occur
distanc
respect
gs
far
away
maintain
function
hydrogen
bond
therefor
lower
bind
energi
lower
dock
score
greater
distanc
drug
consist
biochem
data
two
drug
effect
inhibitor
moreov
effect
inhibitor
cystein
proteas
includ
cathepsin
b
k
l
papain
even
concentr
mm
data
shown
therefor
seem
reason
select
inhibitor
plpro
inhibit
cystein
proteas
presenc
paramet
k
determin
competit
inhibit
model
eq
fig
b
k
inact
k
max
best
fit
satur
equat
eq
fig
r
sqr
respect
experi
repeat
least
three
time
kinet
paramet
k
k
cat
k
best
fit
shown
tabl
use
clinic
treat
leukemia
purin
analogu
effect
anticanc
therapi
convert
nucleotid
hypoxanthin
phosphoribosyl
transferas
vivo
incorpor
dna
prevent
replic
knowledg
first
revers
chemic
inhibitor
document
inhibit
plpro
sarscov
wherea
mani
inhibitor
develop
proteas
sarscov
studi
identifi
two
compound
slowbind
inhibitor
sarscov
plpro
like
compet
bind
site
substrat
current
stage
could
rule
possibl
inhibit
bind
alloster
site
therebi
chang
conform
activ
site
nevertheless
inhibit
competit
revers
select
plpro
although
affin
plpro
mm
rang
could
use
lead
compound
optim
enhanc
potenc
sarscov
mani
c
observ
inactiv
rate
constant
k
inact
panel
b
replot
concentr
solid
line
fit
satur
equat
eq
r
sqr
respect
bestfit
paramet
k
inact
k
max
shown
tabl
experi
repeat
least
three
time
exampl
report
past
success
antivir
treatment
old
drug
light
avail
sever
anim
model
especi
one
infect
mouseadapt
sarscov
reproduc
mani
aspect
human
diseas
includ
morbid
mortal
pulmonari
patholog
would
interest
test
whether
two
drug
effect
block
sarscov
replic
anim
model
importantli
structureact
studi
tabl
identifi
thiocarbonyl
group
moieti
inhibit
plpro
known
two
compound
light
acut
toxic
associ
drug
activ
thiocarbonyl
subset
cystein
proteas
vivo
action
might
complex
realiz
stage
well
document
caus
advers
drug
reaction
signific
number
patient
found
caus
genet
polymorph
thiopurin
smethyltransferas
tpmt
polymorph
produc
tpmt
much
lower
activ
patient
less
abl
metabol
inact
mercaptopurin
result
accumul
subsequ
lifethreaten
myelosuppress
individu
carri
mutat
tpmt
express
fulli
function
tpmt
patient
less
normal
dosag
toler
like
local
high
dosag
might
inhibit
subset
cystein
proteas
therebi
contribut
sever
cytotox
effect
observ
two
drug
furthermor
also
metabol
process
hepat
cytochrom
acid
bind
protein
form
disulfid
bond
thio
moieti
protein
vitro
vivo
whether
acid
form
disulfid
bond
cellular
cystein
proteas
remain
studi
specul
dub
vivo
target
base
studi
mechan
inhibit
plpro
select
structur
similar
plpro
dub
date
potent
select
chemic
compound
avail
inhibit
cellular
deubiquitin
enzym
ubiquitin
aldehyd
develop
laboratori
studi
function
dub
coval
attach
activesit
cy
henc
biolog
consequ
inhibit
dub
clear
moment
moreov
function
deubiquitin
deisgyl
activ
plpro
vivo
also
unknown
vivo
cellular
substrat
adenoviru
encod
deubiquitin
enzym
necessari
process
viral
precursor
protein
virion
matur
isgyl
deisgyl
involv
innat
immun
respons
viral
infect
therefor
whether
inactiv
cellular
dub
contribut
advers
drug
reaction
biolog
consequ
requir
investig
drug
still
use
extens
clinic
especi
children
acut
lymphoblast
myeloblast
leukemia
studi
emphas
import
studi
depth
drug
action
vivo
